Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?

Table 3

Comparison with the literature, median WBRT dose 30 Gy in all studies.

	Own contemporary patients	Mahmoud-Ahmed et al. [7]	Claude et al. [5]	Bartsch et al. [8]	Le Scodan et al. [6]
Treated	2000–2007	1984–2000	1991–2001	1994–2004	1998–2003
𝑛	32	116	120	174	117
Upfront surgery/RS	no	no	yes	yes	no
Median age	55 y.	50 y.	54 y.	55 y.	53 y.
Median interval	52 m.	22.5 m.	38 m.	35 m.	39 m.
Extracranial met.	91%	68%	80%	unknown	94%
Previous Ctx	81%	unknown	84%	unknown	79%
HR positive	42%	unknown	66%	unknown	48%
Median survival	5.0 m.	4.2 m.	5.0 m.	7.0 m.	5.0 m.
1-year survival	31%	17%	25%	30%	28%
Median survival class II	9.0 m.	6.1 m.	9.0 m.	unknown	8.0 m.
Median survival class III	2.4 m.	1.7 m.	3.0 m.	unknown	3.0 m.

RS: radiosurgery, Ctx: chemotherapy, HR: hormone receptor.